trending Market Intelligence /marketintelligence/en/news-insights/trending/05GIcmVl_XL2V6X5yoKJeA2 content esgSubNav
In This List

GlycoMimetics reports updated survival data for leukemia drug in phase 1/2 trial

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


GlycoMimetics reports updated survival data for leukemia drug in phase 1/2 trial

GlycoMimetics, Inc.'s GMI-1271 showed improved survival in patients with acute myeloid leukemia, according to updated data from the company's phase 1/2 trial.

The study involved two groups: 54 patients whose leukemia remained or had returned after prior treatment, also called relapsed/refractory acute myeloid leukemia, or AML, a cancer of blood cells, as well as older patients who were newly diagnosed with the disease.

The study showed that 43% of those with relapsed/refractory AML experienced clinical remission, or the absence of cancer signs and symptoms, for a median duration of 11.1 months.

Overall, though, those who received the drug survived 9.4 months from when they started treatment, a measure also known as median overall survival. This compares to 5.4 months reported previously.

Among older patients with newly diagnosed AML, 68% experienced a clinical remission with a median duration of 14.8 months.

Overall, the median survival rate was 15.8 months for this patient group, which compares to 12 months previously.

GMI-1271 was well-tolerated among both groups, with lower-than-expected rates of mucositis, or ulcers that develop as side effects of chemotherapy.

A phase 3 trial of the drug is scheduled to begin in mid-2018, GlycoMimetics' chief medical officer, Helen Thackray, said in a statement.